DOI : 10.1016/j.bmc.2017.11.010
URL : https://www.sciencedirect.com/science/article/pii/S096808961731790X
Thanks!!
https://www.longevity.technology/mymd-to-commence-phase-2-trial-in-frailty/?utm_source=reddit&utm_medium=social&utm_campaign=frail
We learned a lot about the inhibitor chips in season 1 like how they can be activated, how they shut down the personality of clones, and how they don't always work like they're supposed to. Is there more you want to know about them in season 2 or do you want the BB to move on from them?
>To confirm the antiviral activity of its protease inhibitors against SARS-CoV-2 Omicron variant, Cocrystal conducted an analysis of SARS-CoV-2 lineages covering all reported Omicron variant sequences including those from South Africa, Europe, Asia and North America, and identified one prevalent mutation in the SARS-CoV-2 main protease. Using its proprietary platform technology and assays, the Company further confirmed in vitro antiviral activity of its protease inhibitors against the Omicron variant.
>
>the Company plans to begin a Phase 1 study also as rapidly as possible with an orally administered protease inhibitor.
https://www.sec.gov/Archives/edgar/data/1412486/000149315221032236/ex99-1.htm
Arguing on the cut-off level to detect ketoacidosis in type 2 diabetics on SGLT2i undergoing colonoscopy.
original publication:
https://www.reddit.com/r/ketoscience/comments/mznaav/capillary_ketone_concentrations_at_the_time_of/
comment:
https://diabetesjournals.org/care/article/45/1/e15/139159/Comment-on-Hamblin-et-al-Capillary-Ketone
...
The study on sodiumโglucose cotransporter 2 inhibitor (SGLT2i) therapy by Hamblin et al. (1) advocates for increasing ฮฒ-hydroxybutyrate (BHB) to 1.7 mmol/L for hyperketonemia, in contrast to our previously suggested threshold of 1.0 mmol/L (2). This change is premature, since the new cutoff is based on a nonnormally distributed data set, the risk of developing ketoacidosis is different in patients with diabetes compared with patients without diabetes, and a higher BHB threshold may increase the false-negative rate of early ketoacidosis.
...
response:
...
The cutoff for ฮฒ-hydroxybutyrate concentrations of >1.0 mmol/L is not evidence-based. This was the very reason we undertook our study. Many colonoscopies are carried out in day procedure centers where there is no access to on-site blood gas analyzers or expertise for dextrose-insulin infusions. If the ketone concentration cutoff of >1.0 mmol/L is used, a significant proportion of people would have their procedure canceled, given that 9% of normoglycemic individuals and 24% of sodiumโglucose cotransporter 2 inhibitor (SGLT2i)-treated participants in our study had ketone levels >1.0 mmol/L. The very small risk of diabetic ketoacidosis (DKA) in SGLT2i-treated people undergoing colonoscopy must be balanced by potential delays in detecting and treating colorectal cancer. This is a real concern, given that a recent population-based study showed prediagnostic colonoscopies are associated with 17% lower risk of death from colorectal cancer (4).
...
I have a chance to work with this medicine this weekend. The facilitator says he has had a big download of information and feels like he can consider himself a practitioner. I thought it was going to be ayahuasca. He says this is a similar experience. Just getting a feel for what Iโm in for. Iโve been pretty good about following the same diet I had for my last Ayahuasca experiences. โ๏ธ โค๏ธ
Enrollment now paused in the randomized, double blind, placebo controlled clinical trial in severe and critical hospitalized COVID-19 patients to complete interim analysis
Data from the interim analysis expected in the end of 4th Quarter of 2021 Jules Mitchel, PhD, appointed as strategic advisor to assist with the interim analysis
New York, NY, and Tel Aviv, ISRAEL, Nov. 19, 2021 (GLOBE NEWSWIRE) -- viaย NewMediaWire --
Todos Medical, Ltd.(TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease biology-focused joint venture partner NLC Pharma, Ltd., today is very pleased announce an update regarding the ongoing clinical development of Tollovirยฎ, a oral antiviral 3CL protease (3CLpro, Main protease, Mpro, Nsp5) inhibitor & anti-cytokine therapeutic candidate for the treatment of COVID-19. The enrollment of the 77-patient, Phase 2, randomized, double-blind, placebo controlled clinical trial in hospitalized COVID-19 patients has been paused at the two open clinical sites in Israel, Shaare Zedek Medical Center in Jerusalem and Hillel Yaffe Medical Center in Hadera, to allow for an interim analysis of the data. The Company expects data from the interim analysis to be reviewed by the trial Data Safety and Monitoring Board (DSMB) in the fourth quarter of 2021.
Concurrent with this announcement, the Company announced that it has retained the services of Jules Mitchel, PhD, to assist the Company with the interim analysis. Dr. Mitchel has an extensive background in the clinical trial and regulatory affairs space, previously serving as Founder & CEO of global clinical research organization (CRO) Target Health from its founding in 1993 until it was sold to dMed Biopharmaceuticals in 2019.
The interim analysis, previously scheduled to occur at 33 patients, will now be conducted on the 31 patients enrolled in the trial as of November 10, 2021 based on the recommendation from the statistician using blinded data that indicated the clinical trial has likely met the threshold required to evaluate futility.
The primary endpoints for the trial are:
Reduction in the duration of hospitalization
Time to clinical improvement as
... keep reading on reddit โก
